DA
Therapeutic Areas
Lineage Cell Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| OPC1 | Spinal Cord Injury (SCI) | Phase 1/2a |
| OpRegen | Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) | Phase 2a |
| ANP1 | Sensorineural Hearing Loss | Preclinical |
| VAC2 | Non-Small Cell Lung Cancer (NSCLC) | Phase 1 |
| RPE cells (Genentech Collab) | Degenerative Eye Diseases | Research |
Leadership Team at Lineage Cell Therapeutics
BC
Brian Culley
Chief Executive Officer
JH
Jill Howe
Chief Financial Officer
GA
George A. Samuel III
General Counsel & Corporate Secretary
DK
Derek Kelaita
Vice President of Business Development
JB
Jennifer Bahr-Davidson, Ph.D.
Vice President of Technical Operations
CH
Charlotte Hubbert, Ph.D.
Vice President, Corporate Strategy and Development
RS
Rami Skaliter, M.Sc., Ph.D.
Chief Executive Officer, Cell Cure Neurosciences
MH
Michael H. Mulroy
Chairman of the Board
DA
Deborah Andrews
Director